Corient Private Wealth LP Makes New Investment in Krystal Biotech, Inc. $KRYS

Corient Private Wealth LP acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 32,580 shares of the company’s stock, valued at approximately $12,109,000. Corient Private Wealth LP owned about 0.11% of Krystal Biotech at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Silvant Capital Management LLC bought a new stake in shares of Krystal Biotech in the 2nd quarter worth about $30,000. Western Wealth Management LLC bought a new position in shares of Krystal Biotech in the 1st quarter valued at about $34,000. Greenline Wealth Management LLC purchased a new position in Krystal Biotech in the fourth quarter worth about $34,000. UMB Bank n.a. increased its stake in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares during the last quarter. Finally, Global Retirement Partners LLC increased its stake in Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after acquiring an additional 142 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other Krystal Biotech news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock valued at $16,278,020 over the last ninety days. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $351.46 on Friday. The business’s 50 day moving average price is $348.64 and its 200-day moving average price is $304.16. Krystal Biotech, Inc. has a 1 year low of $136.73 and a 1 year high of $382.54. The firm has a market capitalization of $10.40 billion, a price-to-earnings ratio of 44.04 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 7.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KRYS. Bank of America boosted their target price on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. TD Cowen increased their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Evercore reissued an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Citigroup lifted their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Royal Bank Of Canada started coverage on shares of Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $365.40.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.